The Drug Releasing Balloon contains a dose 3μgr/mm2 of Paclitaxel that adheres to the surface of the balloon through the technique of the micropipeting. The coating contains 21 uniform and homogeneous layers and through a mixture of 1:1 of Paclitaxel and Shellac, ensuring the release of 80% of the drug into the lesion at the deploy of the balloon and not during the crossing of the injury, as it may occur in the competition devices.

The Freeway® Balloon is indicated mainly for the treatment of the femoropopliteal sector and the infrapoplíteo sector in the lower extremities, which is defined as a severe blockage of the blood flow of the lower extremities.

The benefits of the Freeway® DEB:

• Delivers drug locally over a short period of time.
• Avoids chronic inflammation.
• Simplifies the procedure- is as easy to use as a standard PTA.
• Crosses lesions smoothly due to the low profile.
• Respects original vessel anatomy.
• Treats lesions where stents are not a viable solution.
• Allows short-term antiplatelet therapy (3 month).
• Reduces the incidence of restenosis.
• Enables re-intervention.